Intravitreal Bevacizumab for Diabetic Retinopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2/PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2005-12-31

Study Completion Date

2006-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background: to evaluate the 3-month efficacy of a single dose of intravitreal bevacizumab on the progression of severe non proliferative diabetic retinopathy, proliferative diabetic retinopathy and active photocoagulated diabetic proliferative by evaluation of ischemic areas and regression of retinal and disc neovasculrization.

Methods: 40 patients were enrolled in a prospective, interventional study. Patients were treated with intravitreal bevacizumab 0.1ml (0.25mg). We evaluated visual acuity, neovascularization leakage points, capillary closure ischemic areas and macular edema by clinical examination and fluorescein angiography. A clinical examination was performed at baseline and days 1,14 and 30. Active leakage points were measured by fluorescein angiography at 30 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravitreal Bevacizumab vs Photocoagulation for Proliferative Diabetic Retinopathy

NCT00347698

Diabetic Retinopathy

WITHDRAWN PHASE2/PHASE3

Efficacy of Retreatments With Intravitreal Bevacizumab

NCT00406744

TERMINATED PHASE3

Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy

NCT01025934

Proliferative Diabetic Retinopathy

COMPLETED PHASE4

Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema

NCT00417716

Diabetes Mellitus Type 2 Diabetic Macular Edema

WITHDRAWN PHASE3

Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

NCT00599820

Angioid Streaks Choroidal Neovascularization

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Nonproliferative Proliferative Diabetic Retinopathy Active Photocoagulated Diabetic Retinopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intravitreal bevacizumab

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Severe nonproliferative
* Proliferative diabetic retinopathy
* Active photocoagulated diabetic retinopathy

Exclusion Criteria

* Previous vascular occlusion
* Glaucoma
* Uncontrolled hypertension, thromboembolic event
* Renal abnormalities
* Recent or planned surgery
* Coagulation abnormalities
* Panretinal photocoagulation of less than one month before
* Patients with known serious allergies

Eligible Sex

ALL

Accepts Healthy Volunteers

No